WASHINGTON, United States — US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine. Moderna’s experimental mRNA-1010 flu shot is “quadrivalent,” meaning it targets four strains of flu: A/H1N1, A/H3N2, ...